Traditional Chinese medicine research company Regencell Bioscience (RGC) soared Thursday after its CEO Yat-Gai Au personally financed a stock buyback from another shareholder.
RGC stock surged 235.48% to close at $14.09, before pulling back to $11.70 in after-hours trading
Regencell Bioscience’s rally came on the same day as Regencell Bioscience disclosed it purchased 652,000 shares from investment company Digital Mobile Venture, an SEC filing shows.
The company forked over $6.2 million to Digital Mobile Venture, averaging at $9.50 per share, a significant premium to the trading value at the time of the purchase. According to the filing, the buyback was funded by Au.
After the transaction, Au owns a little over 11 million shares, representing 86% of the company.
Not the first rodeo
Although Au’s latest purchase is by far the largest, the Regencell Bioscience founder and CEO has previously bought shares both personally and through Regencell (BVI) Limited — a wholly-owned entity under his control.
- October 30, 2014: Au acquired 10,000 ordinary shares in a private transaction
- September 28, 2020: He transferred these 10,000 shares to Regencell (BVI) Limited
- March 18, 2021: The company issued a convertible note to Au for $3,250,000, automatically convertible into ordinary shares upon the company's initial public offering (IPO)
- July 20, 2021: Upon conversion of the note, Regencell (BVI) Limited received 342,105 ordinary shares
- July 27, 2021 - March 31, 2022: Regencell (BVI) Limited acquired an additional 148,044 ordinary shares through open market purchases, totaling $3,892,055
- July 26, 2022 - August 27, 2024: An additional 7,245 ordinary shares were purchased on the open market for $89,765
- March 10, 2025: Regencell (BVI) Limited agreed to purchase 652,982 ordinary Shares from a third-party shareholder at $9.50 per share, totaling $6,203,329.
What’s behind Regencell Bioscience?
Regencell Bioscience is a biotech company that’s on a mission to commercialize traditional Chinese medicine for ADHD treatment, a subject that hits close to home for Au.
Diagnosed with ADHD as a child, he struggled before finding relief through Chinese therapies. He later graduated from UC Berkeley and held roles at Deutsche Bank and ING Barings before founding Regencell.
Currently, the company only offers ADHD patient appointments in Hong Kong.
Your email address will not be published. Required fields are markedmarked